193 related articles for article (PubMed ID: 11575444)
1. Postprandial GLP-1, norepinephrine, and reactive hypoglycemia in dumping syndrome.
Gebhard B; Holst JJ; Biegelmayer C; Miholic J
Dig Dis Sci; 2001 Sep; 46(9):1915-23. PubMed ID: 11575444
[TBL] [Abstract][Full Text] [Related]
2. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy.
Miholic J; Orskov C; Holst JJ; Kotzerke J; Meyer HJ
Dig Dis Sci; 1991 Oct; 36(10):1361-70. PubMed ID: 1914756
[TBL] [Abstract][Full Text] [Related]
3. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.
Toft-Nielsen M; Madsbad S; Holst JJ
Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105
[TBL] [Abstract][Full Text] [Related]
4. Secretion of glucagon-like peptide-1 and reactive hypoglycemia after partial gastrectomy.
Andreasen JJ; Orskov C; Holst JJ
Digestion; 1994; 55(4):221-8. PubMed ID: 8063025
[TBL] [Abstract][Full Text] [Related]
5. A possible difference in the mechanism for postprandial hypoglycemia associated with dumping syndrome between patients with and without type 2 diabetes.
Hamasaki H; Moriyama S; Yanai H
Obes Res Clin Pract; 2015; 9(6):622-4. PubMed ID: 26321136
[TBL] [Abstract][Full Text] [Related]
6. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
7. A possible role of GLP-1 in the pathophysiology of early dumping syndrome.
Yamamoto H; Mori T; Tsuchihashi H; Akabori H; Naito H; Tani T
Dig Dis Sci; 2005 Dec; 50(12):2263-7. PubMed ID: 16416173
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
[TBL] [Abstract][Full Text] [Related]
10. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.
Näslund E; Bogefors J; Skogar S; Grybäck P; Jacobsson H; Holst JJ; Hellström PM
Am J Physiol; 1999 Sep; 277(3):R910-6. PubMed ID: 10484511
[TBL] [Abstract][Full Text] [Related]
11. Patients With Long-QT Syndrome Caused by Impaired
Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
[TBL] [Abstract][Full Text] [Related]
12. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection.
Miholic J; Orskov C; Holst JJ; Kotzerke J; Pichlmayr R
Digestion; 1993; 54(2):73-8. PubMed ID: 8319842
[TBL] [Abstract][Full Text] [Related]
13. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
14. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
[TBL] [Abstract][Full Text] [Related]
16. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
17. Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.
Øhrstrøm CC; Worm D; Kielgast UL; Holst JJ; Hansen DL
Obes Surg; 2020 Mar; 30(3):1038-1045. PubMed ID: 31907828
[TBL] [Abstract][Full Text] [Related]
18. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
Sonne DP; Hare KJ; Martens P; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G413-9. PubMed ID: 23275610
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
20. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
